All In Biotech

Drug Trial Radar · NCT06319027

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 11, 2024

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.

Conditions

  • Glioblastoma, IDH-Wildtype

Interventions

  • Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance ImagingProcedure

    Undergo DSC-MRI

  • Fluciclovine F18Other

    Given IV

  • Gadolinium-ChelateDrug

    Receive gadolinium-based contrast agent

  • Magnetic Resonance SpectroscopyProcedure

    Undergo MR spectroscopy

  • Positron Emission TomographyProcedure

    Undergo PET scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From biomarker collection to death due to any cause, assessed up to 6 years
  2. Event free survival (EFS)Time frame: From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina · Suspended

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Suspended

  • Edwards Comprehensive Cancer Center

    Huntington, West Virginia · Recruiting

  • West Virginia University Healthcare

    Morgantown, West Virginia · Recruiting

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin · Recruiting

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin · Recruiting

  • Froedtert Menomonee Falls Hospital

    Menomonee Falls, Wisconsin · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Drexel Town Square Health Center

    Oak Creek, Wisconsin · Recruiting

  • Froedtert West Bend Hospital/Kraemer Cancer Center

    West Bend, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.